key: cord-0892637-63l25vfa
authors: Eid, Edward; Abdullah, Lina; Kurban, Mazen; Abbas, Ossama
title: Herpes zoster emergence following mRNA COVID‐19 vaccine
date: 2021-05-03
journal: J Med Virol
DOI: 10.1002/jmv.27036
sha: 7ffd2e9d433d0a3437c70b0cbd439ee6400a575a
doc_id: 892637
cord_uid: 63l25vfa

The current Sars-CoV-2 disease (COVID-19) is a multisystemic disorder of global reach that has demonstrated dire medical and socioeconomic consequences. In an effort to alleviate the morbidity and mortality associated with COVID-19 and halt viral transmission, a host of vaccines has been developed. This article is protected by copyright. All rights reserved.

Dear Editor,

The current Sars-CoV-2 disease (COVID-19) is a multisystemic disorder of global reach that has demonstrated dire medical and socioeconomic consequences. In an effort to alleviate the morbidity and mortality associated with COVID-19 and halt viral transmission, a host of vaccines has been developed. Chief among these vaccines are the messenger RNA (mRNA vaccines that reportedly confer up to 95% protection from COVID-19 after a two-dose series. 1 Common vaccine-related side effects include pain, redness, and/or swelling at the injection site, fatigue, headache, fever, and chills. 1 In what follows, we describe a unique case of varicella zoster virus (VZV) reactivation emerging after vaccination with the mRNA COVID-19 vaccine.

A 79-year-old man with a history of hypertension, coronary artery disease, and antineutrophilic cytoplasmic antibody-related glomerulonephritis presented to our dermatology department with itchy and tender lesions over the right thigh of 1 day duration. At the time of presentation, the glomerulonephritis was in remission and the patient was not on any immunosuppressive therapy for more than 3 months. On further questioning, the patient reported receiving the mRNA COVID vaccine 6 days before the skin eruption.

No other symptoms, such as fever, chills, dyspnea, or cough were noted. On dermatologic examination, a confluence of vesicles, some excoriated and overlying an erythematous base were appreciated scattered over the right thigh in a dermatomal distribution (Figure 1 ). T cells, and natural killer cells. 4 Actually, COVID-19 infection has been shown to be able to reactivate several viruses, including human herpesvirus-6, -7, and Epstein-Barr virus as shown in a recent case of pityriasis rosea during COVID-19. 5 Vaccines can also result in herpes zoster reactivation as previously described in patients receiving inactivated vaccines for hepatitis A, influenza, rabies, and Japanese encephalitis. Recently, the inactivated COVID-19 vaccine has also been incriminated in the resurfacing of herpes zoster. 6 Furthermore, the latency between the manifestation of herpes zoster and the inactivated COVID-19 vaccine was 5 days, akin to our patient. To our knowledge, our case represents the first instance of herpes zoster reactivation following the reception of the mRNA COVID-19 vaccine and the second case of herpes zoster following COVID-19 vaccination of any kind. In light of the recency of the mRNA vaccination technology, a definitive theoretical elucidation of the underlying causes for the VZV reactivation seen in our case remains elusive. However, the mass mRNA

Safety and efficacy of the BNT162b2 mMRNA COVID-19 vaccine

Increased number of herpes zoster cases in Brazil related to the COVID-19 pandemic

Herpes zoster in COVID-19-positive patients

Functional exhaustion of antiviral lymphocytes in COVID-19 patients

Human herpesvirus-6, -7, and Epstein-Barr virus reactivation in pityriasis rosea during COVID-19

Herpes zoster following inactivated COVID-19 vaccine: a coexistence or coincidence?